The influence of prophylactic factor VIII in severe haemophilia A

被引:15
|
作者
Gissel, M. [1 ]
Whelihan, M. F. [1 ]
Ferris, L. A. [1 ]
Mann, K. G. [1 ]
Rivard, G. E. [2 ]
Brummel-Ziedins, K. E. [1 ]
机构
[1] Univ Vermont, Dept Biochem, Colchester, VT USA
[2] Univ Montreal, CHU Ste Justine, Montreal, PQ, Canada
关键词
factor VIII; factor XIII; haemophilia; inhibitory antibody; prophylaxis; thrombin generation; RECOMBINANT FACTOR VIIA; BLOOD-COAGULATION; THROMBIN GENERATION; EXTRINSIC PATHWAY; PLASMA FACTOR; FACTOR-IX; HEMOSTASIS; INHIBITOR; MODEL;
D O I
10.1111/j.1365-2516.2011.02638.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haemophilia A individuals displaying a similar genetic defect have heterogeneous clinical phenotypes. Our objective was to evaluate the underlying effect of exogenous factor (f)VIII on tissue factor (Tf)-initiated blood coagulation in severe haemophilia utilizing both empirical and computational models. We investigated twenty-five clinically severe haemophilia A patients. All individuals were on fVIII prophylaxis and had not received fVIII from 0.25 to 4 days prior to phlebotomy. Coagulation was initiated by the addition of Tf to contact-pathway inhibited whole blood +/- an anti-fVIII antibody. Aliquots were quenched over 20 min and analyzed for thrombin generation and fibrin formation. Coagulation factor levels were obtained and used to computationally predict thrombin generation with fVIII set to either zero or its value at the time of the draw. As a result of prophylactic fVIII, at the time of the blood draw, the individuals had fVIII levels that ranged from <1% to 22%. Thrombin generation (maximum level and rate) in both empirical and computational systems increased as the level of fVIII increased. FXIII activation rates also increased as the fVIII level increased. Upon suppression of fVIII, thrombin generation became comparable in both systems. Plasma composition analysis showed a negative correlation between bleeding history and computational thrombin generation in the absence of fVIII. Residual prophylactic fVIII directly causes an increase in thrombin generation and fibrin cross-linking in individuals with clinically severe haemophilia A. The combination of each individuals coagulation factors (outside of fVIII) determine each individuals baseline thrombin potential and may affect bleeding risk.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 50 条
  • [21] Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables
    Megias-Vericat, Juan Eduardo
    Marques, Maria Remedios
    Haya, Saturnino
    Cid, Ana Rosa
    Querol, Felipe
    Monte, Emilio
    Garcia-Dasi, Maria
    Caunedo, Patricia
    Vila, Carmen
    Bosch, Pau
    Curats, Rafael
    Sanz, Miguel Angel
    Poveda, Jose Luis
    Bonanad, Santiago
    BLOOD, 2016, 128 (22)
  • [22] Relationship between factor VIII replacement therapy and joint damage in severe haemophilia
    Lowe, GDO
    BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 : S3 - S5
  • [23] CURRENT USE OF FACTOR VIII PRODUCTS IN CHILDREN AND ADOLESCENTS WITH MODERATE OR SEVERE HAEMOPHILIA A
    Hirst, C.
    Kessabi, S.
    Farej, R.
    Aubert, R.
    Yao, J.
    Burke, T.
    O'Hara, J.
    VALUE IN HEALTH, 2018, 21 : S459 - S460
  • [24] Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness
    Schlenkrich, S.
    Schubert, C.
    HAMOSTASEOLOGIE, 2013, 33 (03): : 241 - 244
  • [25] Factor VIII inhibitors in patients with congenital severe haemophilia A and its relation to genotype
    Pio, S. F.
    Ozelo, M. C.
    Dos Santos, A.
    De Carvalho, B. V.
    Caram, C.
    Zouain, D.
    Oliveira, G. C.
    Rezende, S. M.
    HAEMOPHILIA, 2012, 18 (06) : e411 - e414
  • [26] A candidate mutation in the factor VIII B domain as a cause of severe canine haemophilia A
    Kamisue, S
    Cameron, C
    Notley, C
    McGlynn, L
    Giles, A
    Lillicrap, D
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS923 - PS923
  • [27] Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A
    Chalmers, E. A.
    Brown, S. A.
    Keeling, D.
    Liesner, R.
    Richards, M.
    Stirling, D.
    Thomas, A.
    Vidler, V.
    Williams, M. D.
    Young, D.
    HAEMOPHILIA, 2007, 13 (02) : 149 - 155
  • [28] Intron 22 factor VIII gene inversions in Argentine families with severe haemophilia A
    De Brasi, C
    Candela, M
    Cermelj, M
    Slavutsky, I
    Larripa, I
    Bianco, RP
    Pinto, MD
    HAEMOPHILIA, 2000, 6 (01) : 21 - 22
  • [29] A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A
    Richards, Michael
    Williams, Michael
    Chalmers, Elizabeth
    Liesner, Ri
    Collins, Peter
    Vidler, Vicky
    Hanley, John
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 (04) : 498 - 507
  • [30] Factor VIII companion diagnostic for haemophilia
    Hu, Chunxiao
    Annese, Valerio F.
    Giagkoulovits, Christos
    Barrett, Michael P.
    Cumming, David R. S.
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2022, 10